Recent Updates
Recently added Catalysts
ENTA Positive Sentiment

Efficacy and Safety of EDP-235 in Nonhospitalized Adults With Mild or Moderate COVID-19: Results From the Phase 2 SPRINT Study

Saturday, April 27, 2024 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: The Phase 2 SPRINT study evaluated the efficacy and safety of EDP-235 in nonhospitalized adults with mild or moderate COVID-19. Results demonstrated promising efficacy and a favorable safety profile, suggesting potential for EDP-235 as a treatment option for this patient population. Further studies may be warranted to confirm these findings.
Price reaction · baseline $12.37 (2024-04-26 close) · clean, no other ENTA news in the window
day 0 close
+7.1%
day 1
+11.1%
day 3 · peak
+12.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • EDP-235 shows promising efficacy in treating mild to moderate COVID-19.
  • The Phase 2 SPRINT study results indicate a favorable safety profile.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~63 mo
Minimal dilution risk
Lead asset
EDP-235
Phase 2 · COVID-19

Full Press Release Details

• About About Us Management Team Board of Directors Timeline
• Pipeline Overview Hepatitis C Virus Respiratory Syncytial Virus SARS-CoV-2 Immunology KIT Inhibition STAT6 Inhibition MRGPRX2
• Science Overview Publications
• Patients Overview Clinical Trials Expanded Access Policy Resources
• Careers Join Us Culture Core Values Testimonials Benefits
• Collaborations Partnering
• Investors Overview Press Releases Events & Presentations Stock Information Stock Quote & Chart Historic Price Lookup Investment Calculator Analyst Coverage Financials Quartlery Results Annual Reports SEC Filings Corporate Responsibility Overview Environmental Social Governance Investor Resources Investor FAQs RSS Feed 2026 Annual Meeting Email Alerts
• Contact Us
• About Us
• Management Team
• Board of Directors
• Timeline
• Overview
• Hepatitis C Virus
• Respiratory Syncytial Virus
• SARS-CoV-2
• Immunology KIT Inhibition STAT6 Inhibition MRGPRX2
• KIT Inhibition
• STAT6 Inhibition
• MRGPRX2
• Overview
• Publications
• Overview
• Clinical Trials
• Expanded Access Policy
• Resources
• Join Us
• Culture
• Core Values
• Testimonials
• Benefits
• Partnering
• Overview
• Press Releases
• Events & Presentations
• Stock Information Stock Quote & Chart Historic Price Lookup Investment Calculator Analyst Coverage
• Financials Quartlery Results Annual Reports SEC Filings
• Corporate Responsibility Overview Environmental Social Governance
• Investor Resources Investor FAQs RSS Feed
• 2026 Annual Meeting
• Email Alerts
• Stock Quote & Chart
• Historic Price Lookup
• Investment Calculator
• Analyst Coverage
• Quartlery Results
• Annual Reports
• SEC Filings
• Overview
• Environmental
• Social
• Governance
• Investor FAQs
• RSS Feed
• Print Page Print Page
• Email Alerts Email Alerts
• RSS Feeds RSS Feeds
• Contact IR Contact IR

Frequently Asked Questions

What is EDP-235?

EDP-235 is a treatment evaluated for its efficacy and safety in nonhospitalized adults with mild or moderate COVID-19.

What were the results of the Phase 2 SPRINT study?

The Phase 2 SPRINT study showed promising efficacy and a favorable safety profile for EDP-235.

Who participated in the SPRINT study?

The study involved nonhospitalized adults diagnosed with mild or moderate COVID-19.

What is the significance of the SPRINT study results?

The results suggest EDP-235 may be a viable treatment option for mild to moderate COVID-19.

ShareAdd on Google
Tags: ENTA Viatris Investor Conferences Healthcare EDP-235 COVID-19 Phase 2 study safety profile
Last updated: Apr 27, 2024

Biotech snapshot

Cash runway
$211M liquidity · $3M/mo burn
~63 mo
Minimal dilution risk
Lead asset
EDP-235Phase 2
COVID-19 →